Abstract Purpose Direct oral anticoagulants (DOACs) are recommended in preference to
vitamin K antagonists (VKAs) for stroke prevention in patients with atrial fibrillation (AF) …

Background: Studies indicate that women with atrial fibrillation (AF) are less likely to receive
anticoagulants despite their higher risk of stroke compared with men. Objective: To evaluate …

Aims To investigate the relationship between body mass index (BMI) and outcomes in
patients with atrial fibrillation (AF). Methods and results In the ENGAGE AF-TIMI 48 trial …

Obesity is well-established as a major cardiovascular (CV) risk factor. Obesity confers a
greater risk for developing atrial fibrillation (AF), but the relation between obesity and …

Extreme obesity—also referred to as severe, grade III, or morbid obesity—is defined as a
body mass index (BMI)> 40 kg/m2, and occurs in 7.7% of the adult US population. 1 This …

Aims The prognostic implication of adiposity on clinical outcomes in atrial fibrillation (AF)
patients treated with oral anticoagulation is unclear. Methods and results A total of 17 913 …

Background: Limited clinical data exist describing the use of direct-acting oral
anticoagulants (DOACs) in patients with body mass index (BMI)> 40 kg/m2 or body weight> …

Background The appropriateness of direct oral anticoagulant (DOAC) dosing has been the
issue in the real-world setting, and inappropriately lower DOAC dose may not be as effective …

Objectives Current evidence indicates that the pharmacokinetic profile of rivaroxaban is not
significantly impacted by body weight. However, real-world data are needed to better assess …

Older patients with atrial fibrillation (AF) are at higher risk of thromboembolic events and oral
anticoagulant (OAC)-related bleeding complications. This meta-analysis evaluates the …